The INHBE Knockout 786-O Polyclonal Cells constitute a CRISPR/Cas9-edited heterogeneous pool derived from the 786-O renal carcinoma line, with disruption of the INHBE gene. This polyclonal knockout cell population provides a loss-of-function model that avoids clonal artifacts. INHBE disruption abrogates inhibin/activin-mediated signaling, enabling functional studies in a defined cancerous background.
The 786-O cell line is a human clear cell renal cell carcinoma (ccRCC) model with well-characterized mutations in VHL and PTEN. These defects result in constitutive HIF pathway activation and altered PI3K/AKT signaling, mirroring genomic features of clinical ccRCC. Its adherent epithelial morphology supports routine culture and downstream assays, making it a robust host for investigating tumor-suppressive mechanisms upon INHBE deletion.
INHBE encodes the inhibin beta E subunit, which dimerizes with INHA to form inhibin E or with other beta subunits to generate activins. These ligands bind heteromeric receptor complexes comprising ACVR2A and ACVR1B, triggering phosphorylation of SMAD2/3. Phosphorylated SMAD2/3 then partners with SMAD4 to translocate into the nucleus and transcriptionally regulate targets such as PAI-1, p21, and Bcl-2 family proteins, governing cell cycle, apoptosis, and differentiation. Upstream modulators include transcription factors FOXO1 and STAT3, while extracellular regulators follistatin (FST) and TGFBR3 fine-tune signal propagation. Cross-talk with the MAPK pathway adds further complexity to cellular responses.
In 786-O cells, INHBE knockout removes a context-dependent tumor-modulatory input. The loss of inhibin/activin signaling may relieve growth suppression or alter invasive potential, influenced by concurrent VHL and PTEN deficiencies. The polyclonal population permits analysis of heterogeneous responses to pathway ablation, revealing the interplay between SMAD and non-canonical MAPK cascades. This model supports dissection of INHBE??s role in ccRCC progression and drug resistance.
These polyclonal knockout cells are designed for functional genomics, signal transduction, and cancer biology studies. Researchers can validate INHBE disruption by RT-qPCR or immunoblotting, analyze phospho-SMAD2/3 levels, and perform proliferation (MTT, BrdU), apoptosis (Annexin V), and migration/invasion assays. RNA-seq enables transcriptome-wide profiling, while co-immunoprecipitation can probe altered receptor?Cligand interactions. The cells are suitable for drug screening to identify compounds that differentially affect INHBE-deficient versus proficient renal carcinoma cells, and for exploring mechanisms of therapy resistance. For further information, please contact Ascent Research.
